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Abstract
Introduction: The World Health Organization (WHO) recommends a CD4 cell count before starting antiretroviral therapy
(ART) to detect advanced HIV disease, and routine viral load (VL) testing following ART initiation to detect treatment failure.
Donor support for CD4 testing has declined to prioritize access to VL monitoring. We examined trends in CD4 and VL testing
among adults (≥15 years of age) starting ART in Southern Africa.
Methods: We analysed data from 14 HIV treatment programmes in Lesotho, Malawi, Mozambique, South Africa, Zambia and
Zimbabwe in 2005 to 2018. We examined the frequency of CD4 and VL testing, the percentage of adults with CD4 or VL
tests, and among those having a test, the percentage starting ART with advanced HIV disease (CD4 count <200 cells/mm3) or
failing to suppress viral replication (>1000 HIV-RNA copies/mL) after ART initiation. We used mixed effect logistic regression
to assess time trends adjusted for age and sex.
Results: Among 502,456 adults, the percentage with CD4 testing at ART initiation decreased from a high of 78.1% in 2008
to a low of 38.0% in 2017; the probability declined by 14% each year (odds ratio (OR) 0.86; 95% CI 0.86 to 0.86). Frequency
of CD4 testing also declined. The percentage starting ART with advanced HIV disease declined from 83.3% in 2005 to 23.5%
in 2018; each year the probability declined by 20% (OR 0.80; 95% CI 0.80 to 0.81). VL testing after starting ART varied;
61.0% of adults in South Africa and 10.7% in Malawi were tested, but fewer than 2% were tested in the other four countries.
The probability of VL testing after ART start increased only modestly each year (OR 1.06; 95% CI 1.05 to 1.06). The percent-
age with unsuppressed VL was 8.6%. There was no evidence of a decrease in unsuppressed VL over time (OR 1.00; 95% CI
0.99 to 1.01).
Conclusions: CD4 cell counting declined over time, including testing at the start of ART, despite the fact that many patients
still initiated ART with advanced HIV disease. Without CD4 testing and expanded VL testing many patients with advanced HIV
disease and treatment failure may go undetected, threatening the effectiveness of ART in sub-Saharan Africa.
Keywords: CD4 lymphocyte count; viral load; Africa; Southern; antiretroviral therapy; highly active; Cohort studies; HIV
infections
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1 | INTRODUCTION
The World Health Organization (WHO) has recommended
immediate initiation of antiretroviral therapy (ART) for all peo-
ple living with HIV since 2015, regardless of CD4 cell count
or clinical stage [1], but WHO still recommends CD4 cell
counts at enrolment into HIV care. The CD4 cell count is the
best way to measure a patient’s immune status prior to start-
ing ART or return to care following treatment interruption,
and is the best predictor of disease progression and risk of
death, especially among those with advanced HIV disease [2-
4]. CD4 cell count is used to guide a number of prophylactic
and diagnostic interventions, including prioritizing testing for
opportunistic infections, such as Cryptococcus or tuberculosis
[5,6].
The primary benefit of ART is the suppression of HIV-1
viral replication [1,7,8]. Suppression of viral load (VL) (defined
by WHO as ≤1000 HIV-RNA copies/mL) reduces morbidity
and mortality among patients living with HIV and onward
transmission of the virus [9]. It is the third of the UNAIDS
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global 90-90-90 and 95-95-95 targets launched in 2014,
which aim to have 73% and 86%, of all people living with HIV
virally suppressed by 2020 and 2030 respectively [10,11].
Since 2013, WHO has recommended VL testing, rather than
CD4 testing, as the preferred monitoring approach to detect
treatment failure following ART initiation [12]. WHO guideli-
nes were further refined in 2016 and currently recommend
routine VL testing six months after starting ART and yearly
thereafter among patients stable on ART [1,7]. Patients
with two consecutive unsuppressed VL measurements
(>1000 copies/mL) despite enhanced adherence counselling,
taken within a three-month interval and at least six months
after starting ART are considered to be in treatment failure
[1,7,12]. Treatment failure indicates either some degree of
drug resistance, or that ART has not been taken properly
[13].
The President’s Emergency Plan for AIDS Relief (PEPFAR)
[14] has been one of the largest financial commitments to
combat HIV/AIDS, supporting more than 50 countries globally,
including more than 20 countries in Africa [14,15]. In 2018,
PEPFAR shifted testing priorities reducing the overall level of
support for CD4 testing to prioritize access to VL monitoring
[16,17]. In this study, we examined longitudinal data from six
countries in the International epidemiology Databases to Eval-
uate AIDS (IeDEA) Southern Africa region, all supported by
PEPFAR since 2008, to assess trends in CD4 and VL testing
between 2005 and 2018.
2 | METHODS
2.1 | Data sources
The IeDEA collaboration (https://www.iedea.org/) is an inter-
national research and data consortium funded by the National
Institutes of Health since 2006 [18-20]. IeDEA is comprised
of seven regional data centres that collect, pool and analyse
existing clinical and epidemiological data on people living with
HIV under care in routine settings as a cost-effective way of
generating large electronic data sets to address high priority
research questions in HIV/AIDS treatment and care that can-
not be answered by single cohorts [21]. Patient-level data,
including patient characteristics, clinic visit history, laboratory
test measurements and medications are collected from pri-
mary through tertiary HIV care facilities across both urban
and rural settings [21]. The IeDEA Southern Africa region cur-
rently contains patient-level data on more than one million
adults and children living with HIV from 17 large treatment
programmes across Lesotho, Malawi, Mozambique, South
Africa, Zambia and Zimbabwe [22].
2.2 | Eligibility criteria
We included all CD4 cell count and VL test measurements
from adults aged ≥15 years who were ART-na€ıve at enrolment
and started ART between 2005 and 2018 at one of the HIV
treatment programmes currently supported by IeDEA South-
ern Africa. We only included public-access programmes that
collect adult CD4 and VL test data using government (i.e. not
privately funded) laboratory services. To ensure adequate time
to capture test measurements we excluded adults who started
ART less than one week before the date of database closure
and adults who had less than six months of possible test mea-
surement data available prior to ART start (e.g. patients who
started ART in the first six months of 2005).
2.3 | Outcomes
We assessed the number of CD4 cell count and VL tests per-
formed by exact calendar date from 1 January 2005 to 31
December 2018, irrespective of whether testing occurred
before or after ART start, and calculated the ratio of CD4 cell
count to VL testing per year over time and stratified by coun-
try. We examined the percentage of adults with a CD4 cell
count at ART start, the percentage of adults with any CD4 cell
count up to six months before ART start, and, among those
with a CD4 cell count, the percentage of adults starting ART
with advance HIV disease by country and calendar year. We
defined ART as a regimen of at least three antiretroviral drugs
from two drug classes, and advanced HIV disease as a CD4
cell count <200 cells/mm3.
We defined CD4 cell count at ART start as a CD4 cell
count taken within a time window of three months before and
up to one week after ART start. In earlier years, it may have
taken several months to initiate ART because of eligibility
requirements and extensive preparation prior to initiation of
therapy [23]. To ensure we captured these earlier CD4 cell
count measurements, we widened the time window to six
months before ART start to assess the percentage of adults
with any CD4 cell count before ART start. If an adult had mul-
tiple CD4 cell count measurements within a time window, we
selected the CD4 cell count measurement closest to ART
start.
WHO recommends VL testing six months after ART start;
however in some parts of Southern Africa regional guidelines
recommend the first VL test at three months for pregnant
and breastfeeding women, and at four months for adults aged
≥15 years [24]. We therefore assessed the percentage of
adults with a VL test three to nine months after ART initiation
to ensure we captured all recommended testing periods and
to allow up to a three-month delay in testing. Among those
with a VL test, we calculated the percentage with an unsup-
pressed VL (>1000 HIV-1 RNA copies/mL). To allow sufficient
follow-up time to undertake VL testing, we excluded adults
who started ART less than nine months before database clo-
sure from the analysis of VL testing. We also excluded adults
who started ART in 2018 because of the small sample size;
the analysis of VL testing thus covered adults starting ART up
to 31 December 2017 and VL testing data up to nine months
thereafter. If multiple VL measurements occurred within the
time window, we selected the first eligible VL measurement.
2.4 | Statistical methods
We used descriptive statistics to summarize baseline charac-
teristics at ART initiation, including percentage female, median
age, median follow-up time and year of ART start stratified by
country. We also used descriptive statistics to characterize
trends in CD4 and VL testing frequency and the proportion
of adults with each test stratified by country. We used a
mixed effect logistic regression model with random intercepts
by country to assess the probability of having a CD4 cell
count at ART start, a VL test after ART start, and among those
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with a test, the probability of having advanced HIV disease or
unsuppressed VL over calendar year adjusted for age and sex.
We created three age categories: <25, 25 to 49 and
>49 years of age. We defined sex as either male or female
and excluded 111 patients with unknown sex or date of birth.
All statistical analyses were performed using Stata version
15.1 (Stata Corp., College Station, TX, USA).
2.5 | Ethical considerations
Local review boards and ethics committees approved the use
of the data included in this study. The Cantonal Ethics Com-
mittee of the Canton of Bern, Switzerland, approved data
merging and the collaborative analyses. Local review boards
and the Cantonal Ethics Committee of the Canton of Bern
waived the requirement to obtain informed consent.
3 | RESULTS
Our main analysis included 502,456 adults from 14 programmes
encompassing more than 300 clinics across six countries in
Southern Africa (Table 1). Three programmes were either paedi-
atric or private and thus excluded from analyses. Median (IQR)
age at ART initiation was 34.3 (28.6 to 41.3) years and 63.7% of
patients were female. Median (IQR) follow-up time was 59.1
(28.8 to 95.3) months, ranging from 39.6 (20.6 to 60.7) months
in Mozambique to 74.5 (39.3 to 107.8) months in South Africa.
Most adults initiated ART in years 2009 to 2013 (43.2%), fol-
lowed by years 2014 to 2018 (38.4%), and 2005 to 2008
(18.4%). The analysis of VL testing after ART start included
458,528 adults (91.3% of adults included in the CD4 count anal-
ysis). Patient characteristics were similar but, as expected as a
result of the broader exclusion criteria, the median follow-up
time was longer (65.1 months) than in the CD4 count analysis
(59.1 months) (Table S1).
3.1 | Frequency of CD4 cell count and VL testing
There was an increase in the frequency of CD4 testing along-
side an increasing number of adults in care in earlier years
(Figure 1). However, in all countries the frequency of CD4
testing plateaued or declined, typically after 2010, despite an
increasing number of adults in care and under follow-up in
subsequent years; Malawi and South Africa had the strongest
declines in testing. Figure 2 shows the frequency of VL test-
ing. In South Africa, VL testing increased steeply in earlier
years, but plateaued after 2011 despite an increasing number
of adults in care. In Zambia, VL testing increased slightly in
earlier years and then waned before increasing sharply in
2015. Malawi experienced a strong increase in VL testing
after 2011. VL testing increased very recently in Lesotho,
Mozambique and Zimbabwe. The ratio of CD4 to VL testing in
the region decreased from a high of 7.2 in 2010 to a low of
0.76 in 2018 (Figure 3). The ratio also decreased in each of
the six countries (Figure S1).
3.2 | CD4 cell count testing at ART initiation
Overall, 61.4% of adults had a CD4 cell count at ART
start, ranging from 31.0% in Malawi to 81.4% in South
Africa (Table 2). The percentage of adults with a CD4 cell
count at ART start decreased over the years from a peak
of 78.1% in 2008 to a low of 38.0% in 2017 with an
increase to 52.2% in 2018 (Figure 4). Among those with
CD4 cell count testing at ART start, 53.6% had advanced
HIV disease (Table 2). South Africa had the highest per-
centage of adults with advanced HIV disease (59.7%) and
Mozambique the lowest (34.1%). The percentage of adults
with advanced HIV disease steadily declined over time
from a high of 83.3% in 2005 to a low of 23.5% in 2018
(Figure 4). Crude trends of the percentage of adults with
a CD4 cell count test at ART start and, among those with
CD4 testing, the percentage with advanced HIV disease by
country are shown in Figure S2.
The probability of having a CD4 cell count at ART start was
14% lower (odds ratio (OR) 0.86; 95% CI 0.86 to 0.86) and
the odds of having advanced HIV disease was 20% lower each
subsequent year (OR 0.80; 95% CI 0.80 to 0.81) (Table 3).
Adults aged 25 to 49 and >49 years had a higher probability
of CD4 cell count testing at ART start and a higher probability
of advanced HIV disease than adults <25 years of age.
Women had a lower probability of CD4 cell count testing at
ART start (OR 0.86; 95% CI 0.85 to 0.87) than men and a
lower probability of advanced HIV disease (OR 0.63; 95% CI
0.62 to 0.64).
Expanding the CD4 cell count testing time window from
three to six months before ART initiation increased the per-
centage of adults with a CD4 cell count at ART start, with the
difference decreasing over time (Figure S3).
3.3 | VL testing after ART initiation
Overall, 17.3% of adults had a VL test three to nine months
after ART start, among whom 8.6% were unsuppressed
(Table 2). South Africa had the highest percentage of adults
with VL testing after ART start (61.0%), followed by Malawi
(10.7%); VL testing was below 2% in all other countries.
Among adults with VL testing, the percentage with unsup-
pressed VL was lowest in South Africa and Malawi (8.5% and
8.5% respectively) and highest in Mozambique (70.6%).
Between 2005 and 2016, the percentage with VL testing fluc-
tuated between 10% and 23%; this increased to 35.7% in
2017 (Figure 4). For all years, the percentage with unsup-
pressed VL among those with VL testing ranged between 7%
and 11%. Crude trends of the percentage of adults with a VL
test after ART start and, among those with VL testing, the
percentage with unsuppressed VL by country are shown in
Figure S2.
The probability of having a VL test three to nine months
after ART start increased modestly over time (OR 1.06; 95%
CI 1.05 to 1.06), but there was no evidence of a decrease in
unsuppressed VL (OR 1.00; 95% CI 0.99 to 1.01) (Table 3).
The probability of having a VL measurement after ART start
was higher for adults aged 25 to 49 years and >49 years than
for adults aged <25 years. However, among those with VL
testing, the probability of having an unsuppressed VL was
lower for adults aged 25 to 49 and >49 years than for adults
aged <25 years. Women had a slightly higher probability of
having a VL test after ART start (OR 1.06; 95% CI 1.04 to
1.09) and a lower probability of unsuppressed VL (OR 0.79;
95% CI 0.75 to 0.83) than men.
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Figure 1. Frequency of CD4 cell count testing per day and cumulative number of adult patients in care by country.
The vertical lines indicate the change in WHO guidelines. Scale of y-axis differs across countries.
Figure 2. Frequency of viral load testing per day and cumulative number of adult patients in care by country.
The vertical lines indicate the change in WHO guidelines. Scale of y-axis differs across countries.
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4 | DISCUSSION
This large study of CD4 and VL testing in ART programmes
from six Southern African countries showed the percentage of
adults with a CD4 cell count at the start of ART declined from
a peak of about 78% in 2008 to below 40% in 2017. Among
those with a CD4 count, the percentage starting with
advanced HIV disease (<200 cells/mm3) also declined, but
almost a quarter of patients still started ART with advanced
HIV disease in 2018. VL testing increased in the earlier years
in South Africa and then plateaued. In the other countries
testing increased in more recent years, but remained modest
considering the large number of patients in care. In 2017,
overall only about a third of patients had a VL measurement
after the start of ART.
The trends in CD4 testing observed in this study likely
reflect changes in ART guidelines. In earlier years, when ART
eligibility was governed by relatively low CD4 thresholds
(<200 cells/mm3 up to 2010 [25], ≤350 up to 2013 [26,27]),
repeated CD4 counts were needed to identify when patients
became eligible for ART. As eligibility expanded to higher CD4
thresholds and, in September 2015, “Treat all” guidance was
introduced recommending all individuals be treated as soon as
possible after diagnosis of HIV infection, less repeat CD4 test-
ing was required [28]. Of note, the peak in the ratio of CD4
to VL testing in 2010 coincides with the release of guidelines
recommending ART during pregnancy and breastfeeding to
reduce vertical transmission under Option B [29]. In the ear-
lier years, WHO and national guidelines recommended routine
CD4 cell count monitoring for patients on ART [27,30].
Figure 3. Trend of the ratio of CD4 cell count testing to viral load testing among adult patients by year of testing.
The vertical lines indicate the change in WHO guidelines.
Table 2. CD4 cell count testing at antiretroviral therapy start (ART) and viral load (VL) testing after ART start among adult patients
Lesotho Malawi Mozambique South Africa Zambia Zimbabwe Total
CD4 cell count at ART start
Total No. of patients
12,441 (100%) 80,365 (100%) 16,178 (100%) 115,667 (100%) 251,816 (100%) 25,989 (100%) 502,456 (100%)
Patients with CD4 cell count testing at ART start
9230 (74.2%) 24,925 (31.0%) 10,472 (64.7%) 94,167 (81.4%) 155,459 (61.7%) 14,199 (54.6%) 308,452 (61.4%)
Patients with advanced HIV disease among those with CD4 cell count testing at ART start
3777 (40.9%) 13,004 (52.2%) 3570 (34.1%) 56,228 (59.7%) 81,450 (52.4%) 7249 (51.1%) 165,278 (53.6%)
VL testing after ART start
Total No. of patients
9386 (100%) 70,887 (100%) 14,698 (100%) 110,520 (100%) 228,699 (100%) 24,338 (100%) 458,528 (100%)
Patients with VL testing three to nine months after ART start
41 (0.4%) 7574 (10.7%) 17 (0.1%) 67,409 (61.0%) 4222 (1.8%) 195 (0.8%) 79,458 (17.3%)
Patients with unsuppressed VL among those with VL testing three to nine months after ART start
12 (29.3%) 646 (8.5%) 12 (70.6%) 5700 (8.5%) 442 (10.5%) 31 (15.9%) 6843 (8.6%)
Number of patients (%) are shown. Because of the shorter study period, the number of patients included in the analyses of VL testing after
antiretroviral therapy (ART) start is smaller (n = 458,528) than the number included in the analysis of CD4 cell count testing at ART start
(n = 502,456). Advanced HIV disease defined as CD4 cell count <200 cells/mm3; unsuppressed VL defined as HIV-1 RNA > 1000 copies/mL.
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However, in 2012 the Southern African HIV Clinicians Society
released new guidelines recommending VL monitoring rather
than routine CD4 cell count monitoring for patients on ART
with a CD4 cell count above 200 cells/mm3 [31]. The follow-
ing year, the WHO and the South African Department of
Health released updated guidelines no longer recommending
routine CD4 cell count monitoring for patients on ART where
VL monitoring was assured [12,32].
The decline in CD4 cell count testing at the start of ART
observed in these six countries and in similar studies is of
concern [33,34]. Although CD4 cell count thresholds for start-
ing ART and CD4 cell count monitoring on ART are no longer
recommended in the “Treat all” era, WHO still recommends
baseline CD4 cell count testing for all patients entering care
and before ART initiation to identify patients with advanced
HIV disease [5,7]. CD4 cell count testing remains important
Figure 4. Trends of CD4 cell count testing at antiretroviral therapy (ART) start and viral load (VL) testing after ART start among adult
patients by year of ART start.(a) The percentage of patients with a CD4 cell count at antiretroviral therapy (ART) start and, among those, (c) the
percentage with advanced HIV disease; and (b) the percentage with a VL test three to nine months after ART start and, among those, (d) the per-
centage with unsuppressed VL by year of ART start. Advanced HIV disease defined as CD4 cell count <200 cells/mm3; unsuppressed VL defined
as HIV-1 RNA > 1000 copies/mL. The vertical lines indicate the change in WHO guidelines.
Table 3. Probability of CD4 cell count testing at antiretroviral therapy (ART) start and viral load (VL) testing after ART start among
adult patients
CD4 cell count at ART start
(N = 502,456)
Advanced HIV disease
(N = 308,452)
VL after ART start
(N = 458,528)
Unsuppressed VL
(N = 79,458)
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Per calendar
year
0.86 (0.86 to 0.86) 0.80 (0.80 to 0.81) 1.06 (1.05 to 1.06) 1.00 (0.99 to 1.01)
Age group in years
<25 1 1 1 1
25 to 49 1.18 (1.16 to 1.21) 1.50 (1.47 to 1.54) 1.45 (1.40 to 1.50) 0.70 (0.65 to 0.76)
>49 1.20 (1.17 to 1.24) 1.48 (1.43 to 1.53) 1.34 (1.28 to 1.41) 0.52 (0.46 to 0.59)
Sex
Male 1 1 1 1
Female 0.86 (0.85 to 0.87) 0.63 (0.62 to 0.64) 1.06 (1.04 to 1.09) 0.79 (0.75 to 0.83)
Results from the mixed-effects logistic regression model showing the probability of having a CD4 cell count at antiretroviral therapy (ART) start, a
VL test three to nine months after ART start and, among those with testing, the probability of having advanced HIV disease and unsuppressed VL
by calendar year, age and sex. CD4 cell count analyses based on 502,456 adults of whom 308,452 (61.4%) had CD4 cell count testing at ART
start; VL analyses based on 458,528 adults of whom 79,458 (17.3%) had VL test testing after ART start. Advanced HIV disease defined as CD4
cell count <200 cells/mm3; unsuppressed VL defined as HIV-1 RNA > 1000 copies/mL.
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because clinical staging has limited diagnostic accuracy for
identifying patients with low CD4 cell count [35]. WHO rec-
ommends a package of interventions among patients with
advanced HIV disease, including screening, treatment and/or
prophylaxis for major opportunistic infections, rapid ART initia-
tion and intensified adherence support [8]. Scaling up access
to this package of interventions to reduce mortality and mor-
bidity is also being supported by major donors such as the
International Drug Purchase Facility (UNITAID) [36]. The
decrease in the proportion of patients with a CD4 cell count
at the start of ART indicates that many patients with
advanced HIV disease may be missed. The percentage with a
CD4 count increased in 2018 to 52.2%. Future analyses of
the IeDEA cohorts will examine whether or not this reversal
of the trend is sustained.
PEPFAR, which provided substantial support to all countries
included in this study, recently shifted their policy away from
routine baseline CD4 cell count testing to prioritize access to
VL monitoring [16,17]. PEPFAR continues to support limited
CD4 testing in countries where more than 10% of patients
start ART with advanced HIV disease [16,17]. We found that
almost a quarter of patients with a CD4 count started ART
with advanced HIV disease in 2018, but many started without
a CD4 cell count. A recent multiregional analysis of IeDEA
data used multiple imputation to adjust for missing CD4 cell
counts and found that although median CD4 cell counts at
ART start increased substantially from 2002 to 2015, the pro-
portion with advanced disease (CD4 cell count <200 cells/
mm3) was around 40% in low-income and middle-income
countries in 2015 [37]. It is likely that the proportion of
patients with advanced HIV disease at the time of initiating
ART is above the PEPFAR threshold of 10%, indicating the
need for continued baseline CD4 cell count testing.
VL testing is the preferred method for monitoring patients
on ART, as treatment failure is identified earlier and more
accurately than CD4 cell count monitoring [5,38]. Despite the
recommendation to switch from CD4 to VL monitoring, a sub-
stantial increase in VL testing parallel to the decrease in CD4
count testing was evident only in South Africa and Malawi. In
the other four countries included in this study, Lesotho,
Mozambique, Zambia and Zimbabwe, the scale-up of VL test-
ing started only very recently. Similar trends have been
observed in other studies of countries in sub-Saharan Africa
[33,39,40]. The higher rate of unsuppressed VL in these latter
countries further indicates they are still transitioning from tar-
geted to routine VL testing.
Two major strengths of this study are the timeliness of data
and the large number of patients: we included data reported
up to 2018 on more than 500,000 people living with HIV in
six countries in Southern Africa. Our study also has several
limitations. The ART programmes and clinics participating in
IeDEA Southern Africa may not represent all treatment facili-
ties located in the region; therefore, the findings in this study
may not be applicable to the country or region as a whole.
The large heterogeneity observed in laboratory testing fre-
quencies among countries in the region further limits the
interpretation of our regional conclusions. Our study did not
account for differences in level of care or access to laboratory
testing that may vary across and within countries and be a
result of different facility type and location. Our study also did
not take into account or attempt to correct for missing
laboratory data. Our study focused on patients who started
ART and did not consider patients lost to follow-up before or
after ART initiation, patients who silently transferred to
another ART programme, or unreported mortality. Lastly, we
were unable to ascertain trends in CD4 cell count testing
among patients with suspected treatment failure, which is rec-
ommended by the WHO and many national guidelines.
Although this study analysed recently collected data, the find-
ings will not reflect the most recent policy changes.
5 | CONCLUSIONS
This large multi-cohort study of people living with HIV in
Southern Africa showed that CD4 cell count testing declined
over time, including testing at the start of ART, despite the
fact that many patients still initiate ART with advanced HIV
disease. Although guidelines and national policies support the
scale-up of VL testing, the coverage of VL testing was low in
most countries. Without CD4 cell count testing and expanded
VL testing many patients with advanced HIV disease and
treatment failure may go undetected, threatening the effec-
tiveness of ART in Southern Africa.
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Table S1. Characteristics of adult patients (aged ≥15 years) at
antiretroviral therapy (ART) initiation by country for the sub-
analysis of viral load testing after ART start.
Figure S1. Trends of the ratio of CD4 cell count testing to
viral load testing among adult patients (aged ≥15 years) by
year of testing and country. The vertical lines indicate the
change in WHO guidelines. N/A: no CD4 cell count or viral
load testing data available for patients in that year.
Figure S2. Trends of CD4 cell count testing at antiretroviral
therapy (ART) start and viral load (VL) testing after ART start by
country. The percentage of adult patients (aged ≥15 years) with
a CD4 cell count at initiation of antiretroviral therapy (ART)
and, among those, the percentage with advanced HIV disease;
and the percentage with a VL test three to nine months after
ART start and, among those, the percentage with unsuppressed
VL by year of ART start. The vertical lines indicate the change in
WHO guidelines. N/A: no CD4 cell count or VL testing data
available for patients in that year. Advanced HIV disease defined
as CD4 < 200 cells/mm3; unsuppressed viral load defined as
measurement HIV-1 RNA > 1000 copies/mL.
Figure S3. Trends of CD4 cell count testing three months ver-
sus six months before antiretroviral therapy start among adult
patients. The percentage of adult patients (aged ≥15 years)
with a CD4 cell count up to three months before antiretrovi-
ral therapy (ART) start and up to six months before ART start
and, among those with testing, the percentage with advanced
HIV disease by year of ART start. The vertical lines indicate
the change in WHO guidelines. Advanced HIV disease defined
as CD4 < 200 cells/mm3.
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